Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...
The American Journal of Managed Care2d
Safety and Efficacy Updates for Asthma and Urticaria Therapies
The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...
Healio3d
Dupilumab, tezepelumab lead biologic initiations for severe asthma
Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...
The American Journal of Managed Care3d
FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
Healio6d
Patients with severe asthma need fewer steroid bursts with tezepelumab-ekko
Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...